Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis
© 2023 American Academy of Neurology..
OBJECTIVES: To examine the agreement between published reference resources for neurofilament light chain (NfL) applied to a large population of people with multiple sclerosis (MS).
METHODS: Six published reference resources were used to classify NfL in participants in the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) network as elevated or normal and to derive age-specific NfL Z-scores. NfL values were classified as elevated if they exceeded the >95th percentile (i.e., Z-score >1.645) of the age-specific reference range. Furthermore, age-specific NfL Z-scores could be derived for 4 of 6 reference resources.
RESULTS: NfL measurements were assessed from 12,855 visits of 6,687 people with MS (median 2 samples per individual [range 1-7]). The mean ± SD age was 47.1 ± 11.7 years, 72.1% of participants were female, disease duration was 15.0 ± 10.6 years, body mass index was 28.6 ± 6.9 kg/m2, and serum NfL was 12.87 ± 12.86 pg/mL. Depending on the selection of the reference resource, the proportion of NfL measurements classified as elevated varied from 3.7% to 30.9%. The kappa coefficient across the 6 reference resources used was 0.576 (95% CI 0.571-0.580) indicating moderate agreement. Spearman correlations between Z-scores derived from the various reference resources exceeded 0.90; however, concordance coefficients were lower, ranging from 0.72 to 0.89.
DISCUSSION: Interpretation of blood NfL values may vary markedly depending on the selection of the reference resource. Borderline elevated values should be interpreted with caution, and future studies should focus on standardizing NfL measurement and reporting across laboratories/platforms, better characterizing the effects of confounding/influencing factors, and defining the performance of NfL (including as part of multimodal predictive algorithms) for prediction of disease-specific outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Neurology - 101(2023), 23 vom: 04. Dez., Seite e2448-e2453 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sotirchos, Elias S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 06.12.2023 Date Revised 29.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1212/WNL.0000000000207957 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363097414 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363097414 | ||
| 003 | DE-627 | ||
| 005 | 20240108135927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1212/WNL.0000000000207957 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1242.xml |
| 035 | |a (DE-627)NLM363097414 | ||
| 035 | |a (NLM)37816633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sotirchos, Elias S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2023 | ||
| 500 | |a Date Revised 29.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 American Academy of Neurology. | ||
| 520 | |a OBJECTIVES: To examine the agreement between published reference resources for neurofilament light chain (NfL) applied to a large population of people with multiple sclerosis (MS) | ||
| 520 | |a METHODS: Six published reference resources were used to classify NfL in participants in the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) network as elevated or normal and to derive age-specific NfL Z-scores. NfL values were classified as elevated if they exceeded the >95th percentile (i.e., Z-score >1.645) of the age-specific reference range. Furthermore, age-specific NfL Z-scores could be derived for 4 of 6 reference resources | ||
| 520 | |a RESULTS: NfL measurements were assessed from 12,855 visits of 6,687 people with MS (median 2 samples per individual [range 1-7]). The mean ± SD age was 47.1 ± 11.7 years, 72.1% of participants were female, disease duration was 15.0 ± 10.6 years, body mass index was 28.6 ± 6.9 kg/m2, and serum NfL was 12.87 ± 12.86 pg/mL. Depending on the selection of the reference resource, the proportion of NfL measurements classified as elevated varied from 3.7% to 30.9%. The kappa coefficient across the 6 reference resources used was 0.576 (95% CI 0.571-0.580) indicating moderate agreement. Spearman correlations between Z-scores derived from the various reference resources exceeded 0.90; however, concordance coefficients were lower, ranging from 0.72 to 0.89 | ||
| 520 | |a DISCUSSION: Interpretation of blood NfL values may vary markedly depending on the selection of the reference resource. Borderline elevated values should be interpreted with caution, and future studies should focus on standardizing NfL measurement and reporting across laboratories/platforms, better characterizing the effects of confounding/influencing factors, and defining the performance of NfL (including as part of multimodal predictive algorithms) for prediction of disease-specific outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Neurofilament Proteins |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Hu, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Matthew D |e verfasserin |4 aut | |
| 700 | 1 | |a Lord, Hannah-Noelle |e verfasserin |4 aut | |
| 700 | 1 | |a DuVal, Anna L |e verfasserin |4 aut | |
| 700 | 1 | |a Arrambide, Georgina |e verfasserin |4 aut | |
| 700 | 1 | |a Montalban, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Akgün, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Ziemssen, Tjalf |e verfasserin |4 aut | |
| 700 | 1 | |a Naismith, Robert T |e verfasserin |4 aut | |
| 700 | 1 | |a Hersh, Carrie M |e verfasserin |4 aut | |
| 700 | 1 | |a Hyland, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Krupp, Lauren B |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholas, Jacqueline A |e verfasserin |4 aut | |
| 700 | 1 | |a Bermel, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Mowry, Ellen M |e verfasserin |4 aut | |
| 700 | 1 | |a Calabresi, Peter A |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzgerald, Kathryn C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology |d 1951 |g 101(2023), 23 vom: 04. Dez., Seite e2448-e2453 |w (DE-627)NLM000034355 |x 1526-632X |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2023 |g number:23 |g day:04 |g month:12 |g pages:e2448-e2453 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1212/WNL.0000000000207957 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2023 |e 23 |b 04 |c 12 |h e2448-e2453 | ||